
In one aspect, there is~~The present invention~~ provides~~d~~ a compound of ~~Formula I~~



Formula I

wherein~~,~~: R^1 is hydrogen or methyl; R^2 is hydrogen or methyl; and R^3~~,~~ R^4, R^5, R^6, or R^7 are independently hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, methylsulfonyl, or trifluoromethylsulfonyl, provided that at least three of R^3, R^4, R^5, R^6 and R^7 are hydrogen; or a pharmaceutically acceptable salt thereof.

The present ~~invention~~disclosure also provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient, carrier or diluent.

The present ~~invention~~disclosure also provides a method of treating cancer selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, stomach cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small-cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, mesothelioma, soft tissue sarcomas, bone sarcomas, leukemia, and testicular cancer in a mammal comprising administering to the mammal an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

In another aspect, there is~~Additionally, this invention~~ provides~~d~~ ~~a~~the compound as defined above~~of Formula I~~, or a pharmaceutically acceptable salt thereof, for use in therapy. Also, this ~~invention~~disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer. In particular, the cancer is selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, stomach cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, mesothelioma, soft tissue sarcomas, bone sarcomas, leukemia, and testicular cancer.

This ~~invention~~disclosure also provides use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in therapy. In another aspect, there is~~Additionally, this invention~~ provides~~d~~ use of a compound as defined above~~of Formula I~~, or a pharmaceutically acceptable salt thereof, in~~for~~ the manufacture of a medicament for use in the treat~~ing~~ment of cancer. In particular, the cancer is selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, stomach cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, mesothelioma, soft tissue sarcomas, bone sarcomas, leukemia, and testicular cancer.

Furthermore, this ~~invention~~disclosure provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient for treating cancer selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, stomach cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, mesothelioma, soft tissue sarcomas, bone sarcomas, leukemia, and testicular cancer.

Particular compounds of Formula I, or a pharmaceutically acceptable salt thereof, are those wherein:

(a) R^1 is methyl;

(b) R^2 is methyl;

(c) R^3, R^4, R^5, R^6, or R^7 are independently hydrogen, fluoro, chloro, trifluoromethyl, or methylsulfonyl;

(d) R^3, R^4, R^5, R^6, or R^7 are independently hydrogen, fluoro, or trifluoromethyl;

(e) at least two of R^3, R^4, R^5, R^6 and R^7 are independently fluoro, chloro, trifluoromethyl, or methylsulfonyl, provided that R^3 and R^7 are not simultaneously hydrogen;

7. The compound according to any one of Claims 1-6 which is 4-fluoro-*N*-methyl-*N*-(1-(4-(1-methyl-1*H*-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of Claims 1-7 which is 4-fluoro-*N*-methyl-*N*-(1-(4-(1-methyl-1*H*-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide hydrochloride.

9. The compound according to any one of Claims 1 or 2 which is 4-fluoro-*N*-(1-(4-(1-methyl-1*H*-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 9 which is 4-fluoro-*N*-(1-(4-(1-methyl-1*H*-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide hydrochloride.

~~9~~11. A pharmaceutical composition comprising the compound according to any one of Claims 1-~~8~~10, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.

~~10~~12. The compound according to any one of Claims 1-~~8~~10, or a pharmaceutically acceptable salt thereof, for use in therapy.

~~11~~13. Use of a compound according to any one of Claims 1-~~8~~10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.